ALPINE IMMUNE SCIENCES INC (ALPN) Stock Price & Overview
NASDAQ:ALPN • US02083G1004
The current stock price of ALPN is 64.97 USD. Today ALPN is up by 0.02%. In the past month the price increased by 0.65%. In the past year, price increased by 583.9%.
ALPN Key Statistics
- Market Cap
- 4.457B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.67
- Dividend Yield
- N/A
ALPN Stock Performance
ALPN Stock Chart
ALPN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALPN. When comparing the yearly performance of all stocks, ALPN is one of the better performing stocks in the market, outperforming 99.78% of all stocks.
ALPN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALPN. No worries on liquidiy or solvency for ALPN as it has an excellent financial health rating, but there are worries on the profitability.
ALPN Earnings
On May 9, 2024 ALPN reported an EPS of -0.28 and a revenue of 7.03M. The company beat EPS expectations (33.62% surprise) and beat revenue expectations (96.1% surprise).
ALPN Forecast & Estimates
15 analysts have analysed ALPN and the average price target is 62.73 USD. This implies a price decrease of -3.45% is expected in the next year compared to the current price of 64.97.
For the next year, analysts expect an EPS growth of -157.63% and a revenue growth -56.25% for ALPN
ALPN Groups
Sector & Classification
ALPN Financial Highlights
Over the last trailing twelve months ALPN reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 60.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.86% | ||
| ROE | -11.07% | ||
| Debt/Equity | 0 |
ALPN Ownership
ALPN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.26 | 402.17B | ||
| AMGN | AMGEN INC | 16.43 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.78 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.72 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.54 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.27 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.69 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.01 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 340.24 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALPN
Company Profile
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Company Info
IPO: 2015-06-17
ALPINE IMMUNE SCIENCES INC
188 East Blaine St., Suite 200
Seattle WASHINGTON 98102 US
CEO: Mitchell H. Gold
Employees: 126
Phone: 12067884545
ALPINE IMMUNE SCIENCES INC / ALPN FAQ
What does ALPN do?
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 126 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
What is the current price of ALPN stock?
The current stock price of ALPN is 64.97 USD. The price increased by 0.02% in the last trading session.
What is the dividend status of ALPINE IMMUNE SCIENCES INC?
ALPN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALPN stock?
ALPN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of ALPINE IMMUNE SCIENCES INC (ALPN)?
ALPINE IMMUNE SCIENCES INC (ALPN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
How many employees does ALPINE IMMUNE SCIENCES INC have?
ALPINE IMMUNE SCIENCES INC (ALPN) currently has 126 employees.
When does ALPINE IMMUNE SCIENCES INC (ALPN) report earnings?
ALPINE IMMUNE SCIENCES INC (ALPN) will report earnings on 2024-08-12, after the market close.